Insight Molecular Diagnostics (IMDX) EBIAT (2020 - 2025)
Historic EBIAT for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to -$10.9 million.
- Insight Molecular Diagnostics' EBIAT rose 1955.83% to -$10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$60.8 million, marking a year-over-year decrease of 4087.24%. This contributed to the annual value of -$60.7 million for FY2024, which is 11836.15% down from last year.
- According to the latest figures from Q3 2025, Insight Molecular Diagnostics' EBIAT is -$10.9 million, which was up 1955.83% from -$9.7 million recorded in Q2 2025.
- In the past 5 years, Insight Molecular Diagnostics' EBIAT registered a high of $6.0 million during Q1 2023, and its lowest value of -$45.0 million during Q4 2022.
- Over the past 5 years, Insight Molecular Diagnostics' median EBIAT value was -$9.7 million (recorded in 2025), while the average stood at -$13.1 million.
- In the last 5 years, Insight Molecular Diagnostics' EBIAT tumbled by 46879.06% in 2021 and then surged by 15790.5% in 2023.
- Quarter analysis of 5 years shows Insight Molecular Diagnostics' EBIAT stood at -$35.9 million in 2021, then fell by 25.34% to -$45.0 million in 2022, then skyrocketed by 64.44% to -$16.0 million in 2023, then crashed by 109.55% to -$33.5 million in 2024, then surged by 67.61% to -$10.9 million in 2025.
- Its EBIAT was -$10.9 million in Q3 2025, compared to -$9.7 million in Q2 2025 and -$6.7 million in Q1 2025.